Application of anti-Xa assay in monitoring unfractionated heparin therapy in contemporary antithrombotic management

References

• Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. JACC. 2000;36:970–1026.
   Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention. JACC. 2011;58:e44–e122.
   Google Scholar
• Hillis LD, Smith PK, Anderson JL, et al. ACCF/AHA guideline for coronary artery bypass graft surgery. Circ. 2011;124:e652–e735.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127:e362–e425.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC guideline for the management of patients with non-ST elevation acute coronary syndromes: executive summary. Circulation. 2014;130:2354–2394.
   PubMed Web of Science ®Google Scholar
• Guervil DJ, Rosenberg AF, Winterstein AG, et al. Activated partial thromboplastin time versus anti-factor Xa assay in monitoring unfractionated heparin continuous intravenous infusion. Ann Pharmacother. 2011;45:861–868.
   PubMed Web of Science ®Google Scholar
• Takemoto CM, Streiff MB, Shermock KM, et al. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring. Am J Clin Pathol. 2013;139:450–456.
   PubMed Web of Science ®Google Scholar
• Fruge KS, Lee YR. Comparison of unfractionated heparin protocols using anti-factor Xa monitoring or activated partial thrombin time monitoring. Am J Health Syst Pharm. 2015;72:S90–S97.
   PubMed Web of Science ®Google Scholar
• Whitman-Purves E, Coons JC, Miller T, et al. Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. Clin Appl Thromb Hemost. 2018;24:310–316.
   PubMed Web of Science ®Google Scholar
• Coons JC, Lasella CJ, Thornberg M, et al. Clinical outcomes with unfractionated heparin monitoring by anti-Xa versus activated partial thromboplastin time. Am J Hematol. 2019;94:1015–1019.
   PubMed Web of Science ®Google Scholar
• Smahi M, De Pooter N, Hollestelle MJ, et al. Monitoring unfractionated heparin therapy: lack of standardization of anti-Xa activity reagents. J Thromb Haemost. 2020;18:2613–2621.
   PubMed Web of Science ®Google Scholar
• Kindelin NM, Anthes AM, Providence SM, et al. Effectiveness of a calculation-free weight-based unfractionated heparin nomogram with anti-Xa level monitoring compared with activated partial thromboplastin time. Ann Pharmacotherp. 2021;55:575–583.
   PubMed Web of Science ®Google Scholar
• American College of Clinical Pharmacists. Anti-Xa PRN Survey for Hospitals. August 22, 2016.
   Google Scholar
• Ranucci M, Cotza M, Isgro G, et al. Anti-factor Xa-based anticoagulation during extracorporeal membrane oxygenation: potential problems and possible solutions. Semin Thromb Hemost. 2020;46:419–427.
   PubMed Web of Science ®Google Scholar
• Mclean J. The thromboplastin action of cephalin. Am J Physiol. 1916;41:250–257.
   Google Scholar
• Murray DWG, Jaques LB, Perrett TS, et al. Heparin and the thrombosis of veins following injury. Surgery. 1937;2:163–187.
   Google Scholar
• Brinkhous KM, Smith HP, Warner ED, et al. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am J Physiol. 1939;125:683–687.
   Google Scholar
• Barritt DW, Jordan SC. Anticoagulant drugs in treatment of pulmonary embolism; a controlled trial. Lancet. 1960;1:1309–1312.
   PubMed Web of Science ®Google Scholar
• Abilgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest. 1968;21:89–91.
   PubMed Web of Science ®Google Scholar
• Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324–327.
   PubMed Web of Science ®Google Scholar
• Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombus. N Engl J Med. 1986;315:1109–1114.
   PubMed Web of Science ®Google Scholar
• Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial . Ann Int Med. 1993;119:874–881.
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC guideline for the management of patients with valvular heart disease. Circ. 2014;129:e521–e643.
   PubMed Web of Science ®Google Scholar
• Biase LD, Gaita F, Elisabetta T, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Heart Rhythm. 2014;11:791–798.
   PubMed Web of Science ®Google Scholar
• Rihal CS, Naidu SS, Givertz MM, et al. SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. JACC. 2015;65:e7–e26.
   Google Scholar
• Sklar MC, Sy E, Lequier L, et al. Anticoagulation practices during venous extracorporeal membrane oxygenation for respiratory failure. Ann Thorac Soc. 2016;13:2242–2250.
   Google Scholar
• January CT, Wann LS, Murray KT, et al. AHA/ACC/HRS focused update on the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. JACC. 2019;74:104–132.
   Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for early management of patients with acute ischemic stroke: 2019 update tot eh 2018 guidelines for the early management of acute ischemic stroke. Stroke. 2019;50:e344–e418.
   PubMedGoogle Scholar
• Succar L, Sulalca EM, Donahue KR, et al. Management of anticoagulation with impella® percutaneous ventricular assist devices and review of new literature. J Thromb Thromb. 2019;48:284–291.
   PubMed Web of Science ®Google Scholar
• Bounameaux H, Perrier A. A half-century of development in the field of antithrombotics - A tribute to Jack Hirsh. Eur J Intern Med. 2020;20:23–24.
   Google Scholar
• Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet . 1980;5(3):204–220.
   PubMed Web of Science ®Google Scholar
• de Swart CA, Niemeyer B, Roelofs JM, et al. Kinetics of intravenously administered heparin in normal humans. Blood. 1982;60(6):1251–1258.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Anand S, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy: heparin a statement for healthcare professionals from the American heart association. Circulation. 2001;103(24):2994–3018.
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants. American college of chest physicians evidenced based clinical practice guidelines (9th Edition). Chest. 2012;141(Suppl):e24S–43S.
   PubMedGoogle Scholar
• Bates SM, Weitz JI. Coagulation Assays. Circulation. 2005;112:e53–e60.
   PubMed Web of Science ®Google Scholar
• Levy JH, Connors JM. Heparin resistance – clinical perspectives and management strategies. N Engl J Med. 2021;385:826–832.
   PubMed Web of Science ®Google Scholar
• Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med. 2017;48:295–313.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol. 2019;10 Article 449:1–9.
   PubMed Web of Science ®Google Scholar
• Grover SP, Mackman N. Intrinsic pathway of coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2019;39:331–338.
   PubMed Web of Science ®Google Scholar
• Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133:511–520.
   PubMed Web of Science ®Google Scholar
• Habib A, Petrucci G, Rocca B. Pathophysiology of thrombosis in peripheral artery disease. Curr Vasc Pharmacol. 2020;18:204–214.
   PubMed Web of Science ®Google Scholar
• Olson JD, Arkin CF, Brandt JT, et al. College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782–798.
   PubMed Web of Science ®Google Scholar
• Nankervis CA, Preston TJ, Dysart KC, et al. Assessing heparin dosing in neonates on veno-arterial extracorporeal membrane oxygenation. ASAIO J. 2007;53:111–114.
   PubMed Web of Science ®Google Scholar
• Bembea MM, Schwartz JM, Nilay S, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J. 2013;59:63–68.
   PubMedGoogle Scholar
• Rolla R, Pergolini P, Vidali M, et al. Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism. Clin Lab. 2014;60:1725–1733.
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Mirochnik O, McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT than APTT-based assays. Br J Biomed Sci. 1999;56:23–33.
   PubMed Web of Science ®Google Scholar
• Girolami A, Cosi E, Ferrari S, et al. Prothrombin: another Clotting Factor After FV That Is Involved Both in Bleeding and Thrombosis. Clin App Thrombosis/Hemostasis. 2018;24:845–849.
   PubMed Web of Science ®Google Scholar
• Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, et al. Clinical scenarios for discordant anti-Xa. Adv Hematol. 2016 Article ID 4054806;2016:1–6.
   Google Scholar
• Beyer J, Trujillo T, Fisher S, et al. Evaluation of a heparin-calibrated antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors. Clin Appl Thromb Hemost. 2016;22:423–428.
   PubMed Web of Science ®Google Scholar
• Eller T, Flieder T, Fox V, et al. Direct oral anticoagulants and heparin: laboratory values and pitfalls in “bridging therapy.” Eur J Cardiothorac Surg. 2017;51:624–632.
   PubMed Web of Science ®Google Scholar
• Plum MD, Hedrick JN, Hockman R, et al. The relationship between the initial anti-Xa measurement and the duration of direct oral anticoagulant influence in patients transitioning to heparin. Pharmcotherapy. 2020;40:880–888.
   PubMed Web of Science ®Google Scholar
• Smith AR, Dager WE, Gulseth MP. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: a retrospective review. Am J Health Sys Pharm. 2020;77:559–565.
   Web of Science ®Google Scholar
• Levito MN, Coons JC, Verrico MM, et al. A systemwide approach for navigating the dilemma of oral factor Xa inhibitor interference with unfractionated heparin anti-factor Xa concentrations. Ann Pharmacotherp. 2021;55:618–623.
   PubMed Web of Science ®Google Scholar
• Ratano D, Alberio L, Delodder F, et al. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thromb Res. 2019;175:53–58.
   PubMed Web of Science ®Google Scholar
• Lardinois B, Hardy M, Michaux I, et al. Monitoring of unfractionated heparin therapy in the intensive care unit using a point-of-care aPTT: comparative, longitudinal observational study with laboratory-based aPTT and anti-Xa activity measurement. J Clin Med. 2022;11:1338.
   PubMed Web of Science ®Google Scholar
• Swayngim R, Preslaski C, Burlew CC, et al. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis. Thromb Res. 2021;208:18–25.
   PubMed Web of Science ®Google Scholar
• Connell NT, Sylvester KW. To aPTT or not to aPTT: evaluating the optimal monitoring strategy for unfractionated heparin. Thromb Res. 2022;218:199–200.
   PubMed Web of Science ®Google Scholar
• Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2021;19:892–908.
   PubMed Web of Science ®Google Scholar
• Kitchen S, Gray E, Mackie I, et al. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: guidance from British committee for Standards in Haematology. Br J Haematol. 2014;166:830–841.
   PubMed Web of Science ®Google Scholar
• Baluwala I, Favaloro EJ, Pasalic L. Therapeutic monitoring of unfractionated heparin – trials and tribulations. Expert Rev Hematol. 2017;10:595–605.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov(Identifier:NCT03426982)
   Google Scholar